Cognitive functioning in new-onset juvenile myoclonic epilepsy.
Assessment
Cognitive functioning
Epilepsy
Juvenile myoclonic epilepsy (JME)
Neuropsychology
Journal
Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
19
12
2019
revised:
28
02
2020
accepted:
28
02
2020
pubmed:
18
3
2020
medline:
20
1
2021
entrez:
18
3
2020
Statut:
ppublish
Résumé
Juvenile myoclonic epilepsy (JME) is a common genetic generalized epilepsy syndrome. Adult patients with JME have shown a neuropsychological profile suggestive of subtle frontal dysfunction, but studies of cognitive functioning in the early phases of JME are rare. We analyzed the cognitive performance data of 18 patients who had undergone a neuropsychological assessment either at the time of JME diagnosis and before the initiation of an antiepileptic drug (AED) treatment (11 patients) or during the first 6 years after JME diagnosis (seven patients). The cognitive performance of the18 patients with JME (mean age: 18.1, range: 15-33 years) and 18 healthy controls (mean age: 18.7, range: 15-25 years) was compared in a retrospective study. The assessed cognitive domains were visuomotor speed, attention, executive function, and verbal memory. The patients with JME and the healthy controls did not differ in any of the assessed cognitive domains. The clinical variables did not correlate to cognitive performance. Furthermore, cognitive performance did not differ between the patients evaluated at the time of diagnosis and before the initiation of AEDs and the patients evaluated during the first 6 years after diagnosis and with an AED treatment. The cognitive performance of patients with new-onset JME was similar to healthy controls. We could not detect the frontal dysfunction that has been suggested to be associated with JME. Patients were in adolescence or early adulthood with a short duration of epilepsy, which may have contributed to the discovery of no cognitive impairments.
Identifiants
pubmed: 32179503
pii: S1525-5050(20)30194-3
doi: 10.1016/j.yebeh.2020.107015
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107015Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest R. Kälviäinen has received grants from the Academy of Finland and Saastamoinen Foundation, speaker's honoraria from Eisai, UCB, and Orion and honoraria for membership of the advisory boards of Eisai, Fennomedical, GW Pharmaceuticals, Sage Therapeutics, Takeda, and UCB. M. Raatikainen, L. Jutila and M. Äikiä have no potential conflicts of interest to report.